Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2017 May 31;16(8):1658–1668. doi: 10.1158/1535-7163.MCT-17-0114

Figure 1. Acquired resistance to ganetespib in KRAS mutant NSCLC leads to loss of ganetespib induced G2/M arrest and docetaxel resistance.

Figure 1

(A) Representative cell cycle analysis at 48 hours after treatment with ganetespib in parental (A549C) and A549-GR100 cells (top). For each group, triplicates were used and average % of G2/M arrested cells was compared between control and GR100 cells in the bar graph (bottom). The two-tailed P values for A549C and A549-GR100 at 50 and 100 nM were < 0.001, and were considered extremely significant (***, p < 0.001) [NS = Not Significant]. (B) Representative MTS assay at 72 hours after treatment with docetaxel in A549C and A549 GR-100. (C) Long term colony formation assay in A549C and A549 GR-100 cells grown in the docetaxel at the indicated doses for 3 days. On day 10, cells were fixed and stained with crystal violet.